Neuroprotection in infant heart surgery.
Neonatal hypoxic-ischemic encephalopathy, prematurity, sepsis-meningitis, and serious forms of complex congenital heart disease requiring infant heart surgery are just a few examples of disorders that share high mortality and morbidity rates. Newborn heart surgery represents a period of planned and deliberate ischemia-reperfusion injury, which is obliged to occur to cure or palliate complex forms of congenital heart disease. Advances in cardiothoracic surgical and anesthetic techniques, including cardiopulmonary bypass and deep hypothermic circulatory arrest, have substantially decreased mortality, expanding the horizon to address functional neurologic and cardiac outcomes in long-term survivors. Interest in the functional status of survivors now stretches beyond the newborn period to childhood, adolescence, and adulthood.
Clancy
Robert Ryan
RR
Department of Neurology, The University of Pennsylvania School of Medicine, PA, USA. clancy@email.chop.edu
D000493:Allopurinol / Q000627:therapeutic use; D006348:Cardiac Surgical Procedures / Q000379:methods*; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D007231:Infant, Newborn; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D016166:Free Radical Scavengers; D018696:Neuroprotective Agents; D000493:Allopurinol